

B
M
C

24. (NEW) The composition of claim 20 wherein the antibody fragment is selected from the group consisting of a $F(ab')_2$ fragment, Fab fragment and linear $F(ab')_2$ fragment.

25. (NEW) The composition of claim 20 wherein the antibody binds CD18, or p185^{HER2}.

26. (NEW) The composition of claim 20 wherein the purity of the antibody in the composition is more than 98%.

27. (NEW) A composition comprising a physiologically acceptable carrier, and a correctly disulfide linked antibody fragment selected from the group consisting of a $F(ab')_2$ fragment, Fab fragment and linear $F(ab')_2$ fragment, wherein the purity of the correctly disulfide linked antibody fragment in the composition is more than about 98%.

28. (NEW) The composition of claim 27 wherein the antibody fragment binds p185^{HER2}.

29. (NEW) The composition of claim 27 wherein the antibody fragment binds CD18.--

REMARKS

Responsive to the Restriction Requirement mailed January 23, 2002, Applicants elect the Group II claims drawn to a composition comprising an antibody. Non-elected claims 1-16 have been cancelled without prejudice or disclaimer, and the composition claims have been recast as claims 19-29 herein, which find former claim/specification basis at least as follows: claim 19 (claim 17); claim 20 (claim 18, and page 7, line 4); claim 21 (claim 8); claim 22 (claims 8 and 9); claim 23 (claim 14); claim 24 (page 7, lines 4-6 and page 32, lines 19-20); claim 25 (page 28, line 27 through to page 29, line 2); claim 26 (page 32, lines 19-20); claim 27 (claims 17-18; page 7, lines 4-6 as well as page 32, lines 19-20; and page 32, lines 19-20); and claims 28-29 (page 28, line 27 through to line 2 on page 29).

In that the amendments do not introduce new matter, entry thereof is respectfully requested. Further prosecution on the merits is awaited.

Respectfully submitted,

GENENTECH, INC.

Date: March 22, 2002

By: W.M.Lee

Wendy M. Lee

Reg. No. 40,378

Telephone No. (650) 225-1994



09157

PATENT TRADEMARK OFFICE